Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer

NCT04225026 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

39

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of study enrollment

Conditions

Esophagitis

Interventions

DRUG: GC4419 (avasopasem manganese)

Sponsor

Galera Therapeutics, Inc.